![Kelvin Neu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kelvin Neu
Direktor/Vorstandsmitglied bei
ZYMEWORKS INC.
Vermögen: - $ am 31.05.2026
Profil
Kelvin M.
Neu is the founder of Herringbone LLC, founded in 2022, and Qdx Technologies Pte Ltd., founded in 2023, where the title held is Chairman.
Current jobs include Director at Zymeworks BC, Inc. since 2020 and Independent Director at Zymeworks, Inc. since 2020.
Former jobs include Independent Director at Idera Pharmaceuticals, Inc. from 2014 to 2019; Director at XOMA Royalty Corp.
from 2012 to 2015; Director at diaDexus, Inc. from 2005 to 2010; Director at AnorMED, Inc.; Independent Director at Aquinox Pharmaceuticals, Inc. from 2017 to 2019; Director at Presidio Pharmaceuticals, Inc.; Director at Prelude Therapeutics, Inc. from 2016 to 2021; Director at IGM Biosciences, Inc. from 2019 to 2021; and Partner at Baker Bros.
Advisors LP from 2004 to 2021.
Education includes undergraduate studies at Princeton University and a doctorate from Harvard Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZYMEWORKS INC. -.--% | 12.01.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Kelvin Neu
| Unternehmen | Position | Beginn |
|---|---|---|
| ZYMEWORKS INC. | Direktor/Vorstandsmitglied | 01.03.2020 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | 16.03.2020 |
Ehemalige bekannte Positionen von Kelvin Neu
| Unternehmen | Position | Ende |
|---|---|---|
| IGM BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 26.01.2021 |
| PRELUDE THERAPEUTICS INCORPORATED | Direktor/Vorstandsmitglied | 25.01.2021 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Portfolio Manager-Aktien | 01.01.2021 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Direktor/Vorstandsmitglied | 09.08.2019 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Direktor/Vorstandsmitglied | 04.06.2019 |
Ausbildung von Kelvin Neu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
53
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology Develops and markets diagnostic products | Health Technology |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops metal based therapeutics | Health Technology |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers and develops small-molecule antiviral therapeutics | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Herringbone LLC
 Herringbone LLC Packaged SoftwareTechnology Services Develops applicant tracking system software | Technology Services |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
